I(E)-2(5.6,7.8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-propenyllphenoxylethyllmorpholine) on stromal cell-mediated hematopoiesis was examined in murine long-term bone marrow cultures. Whether added at week 2 to regenerating cultures or at week 4 to plateau-phase cultures, mofarotene strongly inhibited total cell production in a dose-dependent manner. Progenitor cell production was also inhibited, but to a lesser extent. When added at the initiation of culture, 1 pmol/L mofarotene did not affect formation of the adherent layer, but production of total nucleated cells and progenitors was inhibited over the next 10 weeks by 95% and 96%. respectively. However, after mofarotene treatment ceased, progenitor cell levels began increasing immediately, and cell production reached plateau levels compara-HE AROTINOID MOFAROTENE (Ro 40-8757; 4-(2- there is a protective effect on the hematopoietic system, in addition to the combined antitumor effects. Detailed studies on hematopoiesis in bone marrow (BM) and spleen of treated mice showed that this protective effect was manifested at the progenitor cell level of BM, whereas no protective effect was observed in spleen.',4 Addition of mofarotene to clonal assay cultures of mouse BM cells in the presence of exogenous hematopoietic growth factors has no effect on colony formation.
ble with those of control cultures within 4 weeks. Hematopoiesis was maintained for 14 more weeks, indicating that long-term culture-initiating cells survived the treatment. Assays of spleen colony-forming units (CFU-S) in the adherent layers showed an enrichment of day-l3 CFU-S relative to the more mature day-9 CFU-S. Mofarotene did not inhibit colonyformation by bone marrow cells stimulated by exogenous growth factors and did not decrease production of growth factors by stromal cells in the cultures, as determined by functional assays and by mRNA levels. These results suggest that mofarotene blocks differentiation of very primitive progenitors, inhibiting production of more mature hematopoietic elements.
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tect the hematopoietic system from cytotoxic drugs by inhibiting the entry of primitive stem cells into cell cycle.
MATERIAL AND METHODS

Animuls.
Balblc or C57BV6 mice of either sex, 6 to 10 weeks of age, were obtained from Nippon SLC (Shizuoka, Japan).
Long-term cultures. The method for establishing the LTBMC has been described in detail.'^' Tissue-culture flasks were preincubated overnight at 37°C with 3 mL of IO% fetal calf serum (FCS) in phosphate-buffered saline. After incubation, this was removed and 10 mL of complete LTBMC medium was added to each flask. The basic medium for LTBMCs, EF medium, is a mixture of an enriched Dulbecco's essential medium (GIBCO, Grand Island, NY) and a modified Ham's F12 medium (GIBCO).'.H.y This was further supplemented with l'% FCS, 1 mg/mL of fatty acid-free bovine serum albumin (Sigma, St Louis, MO), 1.4 mmoln L-glutamine (Wako, Osaka, Japan), 10.' mol/L hydrocortisone (Sigma), 8 pg/mL of human transferrin (Wako), I ,ug/mL of insulin (Sigma), 2.1 pg/ mL of linoleic acid (Sigma), and 2.6 pg/mL of cholesterol (Wako). The contents of a single mouse femur were flushed into each flask. Aliquots of 0.1 mL were removed from each Bask and pooled. The numbers of nucleated cells were counted and progenitor cell numbers were determined in clonal assays as described below. The flasks were then sealed and incubated at 33°C. Each week, all the growth medium and nonadherent cells were removed and IO mL of fresh medium was added. Stock solutions of 20 mmol/L mofarotene, Ro 13-7410, Ro 41-5253 were prepared in dimethyl sulfoxide and were further diluted in EF medium just before addition to the cultures. Control flasks were administered dimethyl sulfoxide at a final concentration of 0.0058, equivalent to the high-dose groups of the drugs. Six flasks were used for each experimental group, and the cells were pooled before counting and assay.
In vitro colony$orming assays. These assays were performed essentially as described."'," Briefly, fresh or cultured BM cells were plated in EF medium that was further supplemented with 0.9% methylcellulose (Wako), 10% FCS, 1 % fatty acid-free bovine serum albumin, 1.4 mmolL L-glutamine, 30 pg/mL of transfemn, 9 pg/mL of insulin, 2.1 yg/mL of linoleic acid, 2.6 pg/mL of cholesterol, and nucleosides (Sigma).'"." Conditioned medium from X63 myeloma cells expressing recombinant murine interleukin-3 (IL-3)" and human recombinant erythropoietin (Epo; Wako) were added to give final concentrations of 0.3% and 2 UlmL, respectively. After I O days of incubation at 37°C in a fully humidified atmosphere of 5% COz in air, colonies were counted using an inverted microscope. Colony types were differentiated as colony forming unit-granulo- cyte-macrophage (CFU-GM), burst forming unit-erythroid (BFU-E), and CFU-mixed lineage (Cm-Mix), based on standard criteria of size and color of the constituent cells.
In vivo spleen colony assay. LTBMCs were established using BM cells from C57BU6 mice. Aliquots were taken from each flask for assay of the initial content of in vitro colony-forming cells and in vivo spleen CFU (Cm-S). To some of the flasks, mofarotene was added to give a final concentration of 1 pmoVL. Each week for 3 weeks, the nonadherent cells were removed from the flasks, and the adherent layers were washed 3 times with EF medium to remove loosely adherent cells. These were pooled with the nonadherent cells and represent the suspension cell population. The adherent cells were removed by treatment with trypsin and washed with EF medium before diluting with EF medium containing 10% FCS.
For assay of CFU-S, C57BV6 mice were exposed to a lethal dose of radiation, 900 cGy, at a dose rate of 137 cGylmin in a 13' Csgamma irradiator (Gamma-Cell 40; CSR, Toronto, Canada) filtered with aluminum-copper filters (0.5-mm thick). The animals were injected through a tail vein with 0.2 mL of cells diluted in EF medium containing 10% FCS at appropriate cell concentrations to give between 5 and 30 colonies per spleen in the recipient animals. These concentrations varied, depending on the time of culture. The animals were housed in laminar-flow cage-racks in an environmentally controlled clean room with a 12-hour light-dark cycle at the Laboratory
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Animal Facility (Yokohama City University School of Medicine, Yokohama, Japan). All equipment and supplies, including cages, water, water bottles, wooden chips for bedding, and food pellets, were sterilized. Food and water were given ad libitum. After 9 days, half of the animals were killed, and their spleens were excised and fixed in Bouin's solution. The colonies derived from day-9 (d9) CFU-S were counted using a dissecting microscope. The remaining animals were killed 4 days later to determine numbers of day-l3 (d13) CFU-S. Six animals were used for each experimental point. Treatment of cells from LTBMCs with bromodeoxyuridine (BrdUr) and UV radiation. After 3 weeks of culture, BrdUr (Sigma) and 2'-deoxycytidine were added to LTBMCs that had been established from C57BV6 mice. This time point was selected because it represents the last portion of the regeneration phase, when progenitor cell numbers in the adherent layers are increasing, yet sufficient numbers should be available for the experiment. The final concentration of BrdUr was 0.1 mmoVL and that of 2'-deoxycytidine was 50 p m~l / L '~. Fresh BrdUr and 2'-deoxycytidine were added again after 3 days of incubation. After a total of 7 days of incubation, suspension and adherent cells were removed from control and BrdUr flasks as described above. Aliquots of each cell suspension were irradiated as previously des~ribed'~ with UV light of wavelength greater than 300 nm using a long-UV illuminator (Model UVP; Funakoshi CO, Tokyo, Japan) with A-zone UV, with a peak at 365 nm. The dose exposure estimated by a UV-radiometer (Model 5-221; Funakoshi) was 500 J/mz for wave lengths between 300 and 325 nm. Samples were injected into lethally irradiated C57BU6 mice to determine the numbers of d l 3 CFU-S.
Detection of cytokine mRNA by polymerase chain reaction (PCR). Mofarotene (1 pmoVL) or vehicle was added at week 2 to LTBMCs; and 6 hours, 24 hours, 48 hours, and 7 days thereafter, the medium and nonadherent cells were removed. The adherent layers were washed 3 times with phosphate-buffered saline to remove loosely adherent cells, and RNA was extracted from the adherent cells by the acid-guanidinium thiocyanate-phenol-chloroform extraction method." Total RNA (1 pg) was reverse-transcribed using a GeneAmp PCR kit according to the instructions of the supplier (Perkin Elmer Cetus, Norwalk, CT) using random hexamers. Cytokine RNAs were amplified by PCR amplification using the same kit. The primers for murine IL-la, granulocyte-macrophage colonystimulating factor (GM-CSF), IL-3, transforming growth factor-P (TGF-P), and P-actin were purchased from Clontech (Palo Alto, CA). The primers for murine macrophage-CSF (M-CSF), granulocyte-CSF (G-CSF), and stem cell factor (SCF) were synthesized by Sawadei Tech, Inc (Yokohama, Japan). The 3' primer for M-CSF was 5'-AGGAGTATTGCCAAGGAGGTGTCA-3', and the
5'
primer was 5'-GCTlTAGGGTACAGGCAGTTGCAA-3'. For G-CSF, the 3' primer was 5'-CAGATGGTGGTGGCAAAGT-I"3', and the 5' primer was 5'-CTGGAGCAAGTGAGGAAGAT-3'. The 3' primer for SCF was 5'-TCTTCGGTGCGTTTI%Tr-3', and that for the 5' end was 5'-ATGAAGAAGACACAAACT-3'. The amplification conditions were the same for all the cDNAs except G-CSF cDNA. The first cycle was incubated at 94°C for 5 minutes, at 50°C (60°C for G-CSF) for 2 minutes, and at 72°C for 3 minutes and was followed by 30 cycles of 1 minute at 9 4 T , 1 minute at 50°C (60°C for G-CSF), and 1 minute at 72°C. The final cycle consisted of 5 minutes at 94"C, 2 minutes at 56°C (60°C for G-CSF), and 10 minutes at 72°C followed by cooling at 4°C. The PCR products were separated by electrophoresis on 2% agarose gels.
Statistical analysis. Results of colony assays are reported as the mean of counts from 3 replicate plates, or 6 spleens +-1 SD. LTBMC using a single inoculum of BM provides highly reproducible kinetics of hematopoiesis."' During the first week, cells attach to the bottom and begin to form the adherent layer within which some primitive hematopoietic progenitors survive that will repopulate the flask during the next few weeks (long-term culture-initiating cells [LTC-ICs] ). The numbers of in vitro colony-forming cells in the nonadherent population decrease to a minimum at the end of the first week, and the numbers of nucleated cells are lowest at week 2 (approximately I % of initial). During weeks 3 and 4, progenitor and total cell numbers increase rapidly (control groups in Figs I and 2) . After this increase, there is a maintenance phase that can last several months.
RESULTS
Comparison
In the first experiment. we examined the effect of 1 pmol/ L, 100 nmol/L, and IO nmol/L mofarotene during the regeneration phase of the LTBMC by starting treatment at week 2, when the adherent layers have already formed. For comparison, cultures were also treated with the arotinoid acid Ro 13-7410, which has a similar structure'6 to that of mofarotene. Because Ro 13-7410 is a very potent retinoid, it was tested over a wider range of concentrations, ie, I pmol/L, 10 nmol/L, and 0.1 nmol/L. In addition, the retinoic acid receptor-subtype a (RARa)-specific inhibitor Ro 41 -5253 was also tested at I pmol/L, a dose that completely inhibits differentiation of HL60 cells induced by 10 nmol/L all-trans retinoic acid." The results, summarized in Fig I , show that 1 pmol/L mofarotene has a marked effect on hematopoiesis in LTBMCs, reducing cumulative nucleated cell production during weeks 3 to 8 to 3% of control levels. Table 1) . Total progenitor cell production was inhibited by mofarotene, but to a much lesser extent than that of mature cells, being 24% of control levels during the treatment period (Fig 1 B) . The differential effect of mofarotene on mature cell production relative to progenitor cell production is also reflected in the increased concentrations of progenitor cells per los cells recovered from the mofarotene-treated cultures ( Table l) . The lower doses were much less inhibitory to nucleated cell production. Progenitor cell production was not inhibited by these concentrations of mofarotene.
Mofarotene appeared to specifically inhibit hematopoiesis in these cultures, because the adherent layers were confluent with flat, well-spread cells (Fig 29) . Few, if any, cobblestone Mofarotene, Ro 13-7410, and Ro 41-5253 were added at week 2 (see Fig 1) . Colonies were scored as GM if they contained only granulocytes and macrophages, as E if they contained only erythroid cells, and as E-mix if they contained erythroid plus cells of other lineages. These criteria tend to underestimate the actual proportions of CFU-Mix-derived colonies and overestimate the numbers of CFU-GM-derived colonies."
areas, such as those normally found in control cultures (Fig  2A) , were present after the third week of treatment. From week 6 until the end of week 8 when the experiment was terminated, approximately 90% of the nonadherent cells recovered each week appeared to be nonhematopoietic (data not shown). They were large, round cells with uniform pink staining of the cytoplasm. These cells are probably stromal cells that round up during division. This occurs in control cultures as well, because replating LTBMC cells in new flasks leads to formation of new adherent layers capable of supporting hematopoiesis (J.F. Eliason, unpublished observation). The remaining 10% of the cells recovered from mofarotene-treated LTBMCs appeared to be hematopoietic blast cells.
To determine if the low numbers of progenitors recovered each week from LTBMCs containing 1 pnol/L mofarotene were derived from primitive progenitor cells surviving in the adherent layers, the effect of removing the compound was examined. After careful examination on week 6 to ensure that there were no existing cobblestone areas or even isolated small round cells in the adherent layers, one flask was selected and recharged with medium without mofarotene. Periodically, it was examined for evidence of hematopoiesis. As can be seen in Fig 3, a few round cells appeared after 3 days of culture without mofarotene, and cobblestone areas began to be evident after IO days. When the experiment was terminated after 2 weeks of mofarotene deprivation, 17% of the nonadherent cells recovered from this flask were mature or maturing granulocytes.
Addition of the arotinoid acid Ro 13-7410 also inhibited 1) . One flask from the group treated with l pmollL mofarotene was fed with medium without mofarotene at week 6. Photomicrographs were taken after (A) 3 days (as in Fig 2) and (B) 3 days after a second medium replacement without mofarotene (total of 10 days of incubation without compound).
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From hematopoiesis at the two higher concentrations but not when added at 0.1 nmolL. Production of mature cells and progenitors was inhibited to a similar extent by Ro 13-7410. The kinetics of inhibition also differed from those observed with 1 p m o l L mofarotene (Fig 1C and D) . The cultures treated with Ro 13-7410 appeared to regenerate during weeks 2 through 5 in a similar manner as that of control cultures, but to a lesser extent. However, after week 5, the cultures began to deteriorate. This was particularly evident in the adherent layers, in which the cobblestone areas became smaller and less numerous and the adherent cells appeared less healthy, having numerous granular inclusions (Fig 2C) . The RARa-specific antagonist Ro 41-5253 at 1 pmoVL had little effect on nucleated cell and progenitor cell production. The kinetics of hematopoiesis in these cultures were parallel to those of the control cultures. The most striking feature of these cultures was the large number of fat-containing cells in the adherent layer (Fig 2D) . Fat cells are seldom seen in LTBMCs with active hematopoiesis under these culture conditions.'
Effect of time of mofarotene addition on inhibition of hematopoiesis in LTBMCs. To determine if mofarotene inhibited establishment of cultures and to obtain an estimate of the maturity of the progenitor cells affected by its presence in culture, the time of starting treatment was varied. Mofarotene was added to some cultures at the initiation of culture, to some at the beginning of the regeneration phase on week 2, and to others at the beginning of the plateau phase at week 4. Because the previous experiment indicated a very steep dose-response relationship between 1 pmol/L and 0.1 pmol/L, lower concentrations of 0.6 p m o l L and 0.3 ,umol/ L were also tested at the latter two time points. The cultures were treated with mofarotene until week 10, and, thereafter, the cultures were fed with normal medium without mofarotene, so that the reversibility of the inhibitory effects could be examined in more detail. Cultures that had contained the lower doses of mofarotene were monitored until week 14, and those treated with 1 pmoVL were followed up until week 24.
The results for total nucleated cell and progenitor cell recoveries from these cultures are summarized in Fig 4. The addition of mofarotene at the initiation of the culture had no effect on the establishment of the adherent layer or on recovery of nonadherent cells or progenitor cells after 1 week of culture (Fig 4A and B) , indicating that it is not toxic. By the second week, when progenitor cells began to repopulate the control cultures, the numbers of progenitors recovered from mofarotene-treated cultures continued decreasing to levels below 1% of the initial numbers inoculated into the flasks. Nucleated cell and progenitor cell production remained low throughout the treatment period, with cumulative recoveries for weeks 1 to 10 of 5% and 4% as compared with those of control levels, respectively.
When mofarotene was added at week 2 (Fig 4C and D) , hematopoietic cell numbers increased for the next 2 weeks and then decreased during the next 2 weeks to levels that were related to mofarotene dose. Cumulative cell recoveries during weeks 3 to 10 were 2% of control cultures for LTBMCs with 1 p m o l L mofarotene, 7% for LTBMCs with during weeks 5 to 10 was 8% of that of control in LTBMCs containing 1 pmol/L mofarotene, 26% with 0.6 pmoVL, and 27% with 0.3 pmol/L. Progenitor cell production was 34% of that of control with 1 pmol/L mofarotene, 49% with 0.6 pmoVL, and 41% with 0.3 pmol/L.
The inhibitory effect of mofarotene was completely reversible under all the treatment conditions. Progenitor cell production began to increase within 1 week of removal of the compound. In cultures treated with 1 pmol/L mofarotene, the rate of recovery was the same regardless of the time of treatment. Peak numbers of progenitors were observed on weeks 13 to 14 at levels that were 2.5-to 4-fold greater than that originally inoculated into the flasks. In the lower dose groups, in which inhibition was less severe, recovery was earlier. For instance, in LTBMCs to which mofarotene was added on week 2 (Fig 4D) , peak recovery of progenitor cells occurred by week 14 in cultures that had contained 1 pmoV L mofarotene, by week 12 in those with 0.6 pmoVL, and by week 11 in those with 0.3 pmol/L. The recovery kinetics of total nucleated cells were similar to those of progenitors, although no increase was observed before week 12 in LTBMCs treated with 1 pmol/L mofarotene. At this dose, cell production reached plateau levels at weeks 14 to 15 and remained at or above control levels until the experiment was terminated at week 24.
Effect of mofarotene on colony formation by fresh BM cells. To confirm our previous finding that mofarotene has no effect on proliferation and maturation of progenitor cells detected in vitro (CFU-GM, BFU-E, and CFU-Mix), the effect on fresh BM cells of various concentrations of mofarotene, covering the range used in the experiment shown in Fig 4, was examined. There was no significant inhibition up to a concentration of 3 pmoVL (Fig 5) .
Effect of mofarotene on production of CFU-S in LTBMCs.
The kinetics of cell recovery after removal of mofarotene reaching plateau levels only after 4 to 5 weeks suggest that the surviving progenitor cells in the cultures are arrested at a very early stage. To examine this more closely, we examined the numbers of d9 and d l 3 CFU-S in adherent layers during the first 3 weeks of culture in the presence of 1 pmoV L mofarotene. The results from 2 independent experiments are shown in Table 2 . During the first week, the numbers of CFU-S recovered in the adherent layers were approximately 0.1% of their initial levels in experiment 1 and 1% of initial levels in experiment 2. For comparison, the CFU-GM decreased to approximately 0.1% to 0.2% of that of initial levels in the first experiment and 10% to 20% in the second. The results for d9 and dl3 CFU-S at week 1 were similar to each other, as were the results for control and treated cultures. During the second and third weeks, however, there was an increase in both d9 CFU-S and d l 3 CFU-S in the adherent layers of control LTBMCs. By week 3, d9 CFU-S numbers had increased 57-fold and 11-fold in the two experiments, and dl3 CFU-S had increased 30-fold and 15-fold. The ratio of d l 3 to d9 CFU-S was less than 1 in these cultures, except at week l in experiment 1 when it was 1.5 and at week 3 in experiment 2 when it was 1.2. In contrast, there was little or no increase in d9 CFU-S in mofarotenetreated cultures (50% decrease in experiment 1 and 1.8-fold increase in experiment 2). In each experiment, there was a modest increase in treated LTBMCs of dl3 CFU-S by week 3 (3.4-fold and 3.8-fold), and, at all times, the numbers of Cultures were established with BM from C57B1/6 mice. Mofarotene ( 1 pmol/L) was added at week 0. BrdUr was added on week 3, and cells
Abbreviations: S, suspension cells; A, adherent cells; ND, not determined.
were harvested on week 4.
d l 3 CFU-S were greater than those of the more mature progenitors.
These results suggest that mofarotene may prevent the d l 3 CFU-S from dividing and giving rise to new d9 CFU-S. To test this possibility, we examined the sensitivity of these progenitors to labeling with BrdUr and subsequent radiation with near-UV The results shown in Table  3 indicate that the l-week labeling period with BrdUr was quite toxic to the hematopoietic cells in these cultures, reducing the numbers of nonadherent cells in control LTBMCs by 94% and adherent cells by 85%. Most of the cells killed in the adherent layer represented hematopoietic rather than stromal cells, because only 39% of the adherent cells were killed by BrdUr in mofarotene-treated LTBMCs in which there are few hematopoietic cells. Suspension cells in treated cultures were hardly affected by BrdUr, but there were very few recovered even in its absence. Most of the in vitro colony-forming cells and dl3 CFU-S were killed by BrdUr. However, of those cells that remained alive after labeling, all of the suspension CFU-S and 65% of the adherent CFU-S from control cultures were killed by UV radiation, whereas only 5% of the adherent CFU-S from treated cultures were killed There were insufficient numbers of suspension cells in the treated cultures to be tested.
Effect of mofarotene on cytokine production in LTBMCs. The possibility that the inhibitory effect of mofarotene might be mediated by induction of inhibitory factor production by stromal cells was examined by assaying growth medium from control and mofarotene-treated LTBMCs in a clonogenic assay with BM cells. The media were conditioned for 1 week of culture before assay. As expected, medium from control cultures had little colony-stimulating activity (Table  4) and did not inhibit colony formation in the presence of IL-3 plus Epo. Medium from mofarotene-stimulated cultures also did not inhibit colony formation in the presence of exogenous growth factors but, in contrast to medium from 100 ND 65 control cultures, had significant colony-stimulating activity on its own.
The effect of mofarotene on levels of cytokine mRNAs in LTBMCs at various times after medium replenishment was examined by PCR. The results are summarized in Fig  6 . At 6 and 24 hours after feeding, mRNAs for G-CSF, ILl a , and TGF-0 were clearly visible and were not changed by mofarotene treatment. At no time was IL-3 mRNA detected, and that for GM-CSF was detected in several experiments as a very faint band (not visible in Fig 6) , but only at the 6-hour time point. No major differences were observed 
DISCUSSION
Previous work with mofarotene has shown that it not only has antitumor activity in model systems, but also protects progenitor cells in BM of animals treated with the hematotoxic drugs cyclophosphamide' and 5-FU.4 The BM specificity of this effect and the fact that colony formation stimulated by exogenous growth factors is not affected by mofarotene suggests that the BM microenvironment may play an important role in mediating the effect of mofarotene. Two possible mechanisms can be postulated to explain the protective effect.'" The first is that mofarotene may induce production of hematopoietic growth factors by the stromal cells, thereby increasing the recovery rate of the hematopoietic system after depletion. The second possibility is that mofarotene may inhibit proliferation of primitive progenitor cells, thus protecting them from being killed. Therefore, we examined the effect of mofarotene in LTBMCs in which the interaction between stromal cells and hematopoietic progenitors models well the in vivo situation in BM"' and found that it markedly inhibited hematopoiesis, although it was not toxic to the hematopoietic or stromal elements.
Mofarotene shares structural features with the arotinoid class of retinoids, but does not bind to nuclear retinoic acid receptors, RARa, RARP, or RAR y.'." However, long-term treatment of animals with mofarotene gives rise to sideeffects reminiscent of hypervitaminosis A syndrome,' perhaps through formation of an RAR-binding metabolite. The retinoids all-frons retinoic acid and its isomer 9-cis retinoic acid, which is the ligand for the RXR family of nuclear receptors, have been reported to have stimulatory effects when tested with unfractionated BM in vitro" and inhibitory 24hr 48hr 7d
effects on proliferation and differentiation of purified hematopoietic progenitors."," One explanation for the discrepancy is that these retinoids stimulate production of M-CSF and GM-CSF by stromal cells.'s We examined the effect of the arotinoid acid Ro 13-7410 in our LTBMCs and found that it also inhibited hematopoiesis, although in a somewhat different manner from that of mofarotene, with different kinetics and by apparently affecting the function of the stromal cells, because mature and immature hematopoietic cells were reduced to similar extents. Inhibition in the retinoid-treated cultures appeared very similar to that observed in cultures treated with tumor necrosis factor-m,' which also induces production of colony-stimulating factor in stromal cells. 25 Another retinoid tested in the cultures for comparison was the RARa-specific antagonist Ro 41-5253, which binds to RARa but does not activate it.'7.26 This is of interest, because LTBMCs are primarily granulopoietic cultures, and recent evidence suggests that RARa is important for granulocyte differentiation. In acute promyelocytic leukemia (M3). the t( 15: 17) chromosomal translocation specifically results in a fusion between RARa and the PML gene, giving rise to an inactive RARCU.'~.*'~ Furthermore, transfection of a multipotential cell line3" or mouse BM cells." with a dominant negative mutant RARm inhibits granulocytic maturation in the absence of pharmacological doses of all-frons retinoic acid. No effect on hematopoiesis was evident in LTBMCs treated with Ro 41-5253. The major effect of this compound was to increase the numbers of adipocytes in the adherent layer. This indicates that RARm is important for the negative regulatory effect of retinoids in adipocyte differentiation that has been reported."-''
In contrast to the effects of the retinoid agonist and antagonist, inhibition by mofarotene was much more profound but was reversible. This inhibition appeared to be due to a block at the level of very primitive progenitor cells. The finding that d9 CFU-S generation in mofarotene-treated cultures was For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From less than that of d l 3 CFU-S indicates that the block occurs at or before the d l 3 stage. Our results with BrdUr and UV radiation indicate that there is a very small subpopulation of d l 3 CFU-S in the adherent layers of LTBMCs that are not killed during a l-week labeling period. In control cultures, only 2% of the CFU-S survived this treatment, whereas 6% survived in LTBMCs containing mofarotene, thus suggesting that these cells remained out of cycle for the entire week. The kinetics at which hematopoiesis recovered in the cultures after removal of mofarotene were identical to those of freshly initiated cultures, and hematopoiesis in these rescued cultures was able to continue for at least 14 weeks more, showing that the surviving progenitor cells have the same repopulation capacity as LTC-ICs. Murine LTC-ICs are closely related to, if not identical to, true hematopoietic stem cell^.'^ Therefore, it appears that the block occurs in progenitors representing a very primitive developmental stage. The varying rate at which hemopoiesis decreases, depending on the time of addition of mofarotene between week 0 and week 4, can be explained by the increased numbers of more mature progenitors, comparable with in vitro colony-forming cells CFU-GM, CFU-Mix, and BFU-E, existing within the adherent layer at the later time points. These progenitors are not inhibited by mofarotene and continue to divide and produce mature progeny for several weeks after its addition to the cultures. Finally, their numbers become depleted because they are not being replenished from the stem cell pool. Therefore, week 4 cultures with much hematopoietic activity in the adherent layer take longer to deplete than do 2-week-old cultures.
We examined whether mofarotene affects synthesis of various hematopoietic regulatory molecules, because it has been shown to inhibit autocrine growth of pancreatic cancer cells by downregulating production of TGF-a and its receptor, the epidermal growth factor receptor.'s Our results using a PCR assay showed that G-CSF, M-CSF, and IL-I a were constitutively expressed in these cultures. As previously shown by Northern analysis, no mRNA for IL-3 was detected, and GM-CSF was only transiently detected early after feeding the cultures. 6 Mofarotene did not significantly downregulate expression of any of these positive regulatory molecules, and, in fact, SCF appeared to be upregulated at some time points.
Another mechanism by which mofarotene could inhibit stem cell proliferation in LTBMCs would be by induction of the production of a negative regulator of hematopoiesis. Several such regulators have been described. One is the tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro-OH." However, recent evidence suggests that, in long-term cultures, it has an indirect effect on hematopoietic progenitor cells mediated by another factor, possibly macrophage inflammatory proteinla (MIP-la).j7 We have not examined production of MIPl a in mofarotene-treated murine cultures, but studies with human BM cells have shown that it does not suppress hematopoietic cell production over 5 to 8 weeks of treatment."
In addition, MIP-la does not protect long-term repopulating cells in the BM of mice receiving repeated injections of 5-FU3' under conditions similar to those in which a survival advantage for mice treated with mofarotene has been observed.' A third factor that inhibits hematopoiesis in L T B M C S~" .~~ and protects mice from lethal effects of 5-FU3' is TGF-P. Our results confirm that TGF-P is constitutively produced in LTBMCS.",~ However, mofarotene did not affect the levels of TGF-0 mRNA in the adherent layers.
Although it is possible that changes may occur in expression of other positive or negative regulatory molecules that we did not examine, when LTBMCs are treated with mofarotene, an alternative explanation is that mofarotene could act directly on hematopoietic progenitor cells. The BM specificity of the effect in vivo might then be due to the fact that the majority of stem cells resides in BM. One mechanism of action of mofarotene that could be involved is its effect on mitochondrial gene tran~cription.~~ Hematopoietic stem cells are proposed to be noncycling cells in a resting state (G"), which is considered to be important for their protection from DNA damage." Active oxygen species that are produced in mitochondria are important mutagens and tumor promoters. 47 Cell separation studies with rhodamine-123, a mitochondria-specific dye, have shown that the most primitive hematopoietic progenitor cells are in the subpopulation with the lowest ~taining.~'~'') The issue is complicated by the fact that these same progenitors express P-glycoprotein," the multidrug resistance efflux pump protein, and rhodamine is a substrate for this molecule.'* However, evidence suggests that when the activity of P-glycoprotein in these cells is accounted for, either indirectly by sorting cells first with Hoechst 33342 (another P-glycoprotein substrate) before staining with rhodamine 123'j or directly by sorting in the presence of erap pa mil,^^ rhodamine staining is still low.
Thus, mofarotene could act to keep cells in G, by preventing upregulation of the mitochondrial gene expression necessary for entry into the active cell cycle.
Mofarotene has marked inhibitory effects on hematopoiesis in murine LTBMCs that are completely reversible. Although the mechanism of action on hematopoietic stem cells remains to be clarified in detail, it appears to prevent primitive hematopoietic stem cells from entering into cell cycle. This compound could be a useful tool for manipulating stem cell cycling status For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From
